OS Therapies (NYSE:OSTX) Receives Buy Rating from D. Boral Capital

Posted by Lorenzo Tanos on Jan 31st, 2025

D. Boral Capital restated their buy rating on shares of OS Therapies (NYSE:OSTX – Free Report) in a research report report published on Thursday morning,Benzinga reports. The firm currently has a $20.00 target price on the stock.

Separately, Maxim Group upped their price target on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, January 16th.

View Our Latest Report on OS Therapies

OS Therapies Stock Down 25.0 %

Shares of OSTX opened at $1.95 on Thursday. OS Therapies has a twelve month low of $1.58 and a twelve month high of $7.00. The firm’s 50 day moving average price is $3.42.

Insider Buying and Selling at OS Therapies

In other news, major shareholder Shalom Auerbach sold 16,720 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total value of $112,692.80. Following the transaction, the insider now owns 2,531,211 shares in the company, valued at $17,060,362.14. This represents a 0.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC purchased a new stake in shares of OS Therapies Inc (NYSE:OSTX – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

(Get Free Report)

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.